Brookdale Senior Living, Inc. (BKD)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-30
$10.39+1.17%
Close 2026-10-30 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-30
Research Workspace
Put BKD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 4% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens weak on capital allocation, earnings delivery, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 43% in its worst 12-month stretch.
View RiskBKD’s portfolio purchases support its optimization plan, though revenue declined year over year. Recent performance is strong, but the company remains unprofitable. Second-quarter fiscal 2026 revenue fell 11% year over year, despite an earnings beat. BKD trades at 0.8 times sales versus a 1.0-times peer median. The price reflects less growth than our forecast. Management is behind on a stated commitment. Our model puts the next-quarter miss probability at 27%. Peer multiples imply a price about 21% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. BKD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering BKD (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare BKD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BKD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put BKD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Optimize portfolio through community dispositions and acquisitions
Acquisition aligns with portfolio optimization objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Optimize portfolio through community dispositions and acquisitions
Acquisition aligns with portfolio optimization objective.
Advances: Optimize portfolio through community dispositions and acquisitions
Acquisition aligns with optimizing portfolio strategy.
Advances: Increase RevPAR by 8% to 9% in 2026
Occupancy gains support RevPAR growth objective.
Threatens: Optimize portfolio through community dispositions and acquisitions
Real estate bets may hinder portfolio optimization amid occupancy issues.
Advances: Maintain Adjusted EBITDA guidance for 2026
Portfolio shrinkage suggests improved earnings potential.
Advances: Increase RevPAR by 8% to 9% in 2026
RevPAR growth aligns with management's growth objectives.
Threatens: Maintain Adjusted EBITDA guidance for 2026
Revenue decline and debt increase threaten EBITDA guidance.